Genomic Health Updates Analysts on Companion Dx Pipeline, New Education Campaign | GenomeWeb

By Turna Ray

Updating analysts on its ongoing work with drug companies during a conference call this week, Genomic Health said it may develop a companion test for Bristol-Myers Squibb/Imclone/Lilly's colorectal cancer drug Erbitux that gauges markers in addition to KRAS.

Genomic Health said it is also writing up a study on a companion test it is developing for Pfizer's renal cancer drug Sutent.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.